PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection.
about
Optimisation of antiretroviral therapy in HIV-infected children under 3 years of ageEffectiveness of antiretroviral therapy in HIV-infected children under 2 years of ageHigh drug resistance prevalence among vertically HIV-infected patients transferred from pediatric care to adult units in SpainImpact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.Impact of antiretroviral therapy on opportunistic infections of HIV-infected children in the therapeutic research, education and AIDS training asia pediatric HIV observational database.Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunologyA retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa.Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial.Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older.Guidance on vaccination of HIV-infected children in Europe.Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric populationLong-term virological outcome in children on antiretroviral therapy in the UK and Ireland.Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents.Post-licensing safety of fosamprenavir in HIV-infected children in Europe.Risk of triple-class virological failure in children with HIV: a retrospective cohort studyFirst-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children.Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children.Delayed reconstitution of B cell immunity to pneumococcus in HIV-infected Malawian children on antiretroviral therapy.Virtual support for paediatric HIV treatment decision makingPRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naïve and -experienced infants and children aged ≥3 months to <6 years.Induction maintenance concept for HAART as initial treatment in HIV infected infants.HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.Outcomes after viral load rebound on first-line antiretroviraltreatment in children with HIV in the UK and Ireland: an observational cohort studyEarly antiretroviral therapy in HIV-1-infected infants, 1996-2008: treatment response and duration of first-line regimens.Pharmacotherapy of pediatric HIV infectionHigh virologic response rate after second-line boosted protease inhibitor-based antiretroviral therapy regimens in children from a resource limited settingAntiretroviral treatment, management challenges and outcomes in perinatally HIV-infected adolescentsPopulation pharmacokinetics of abacavir in infants, toddlers and children.Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.[Treatment failure in children infected with HIV in routine follow-up in a resource-limited setting in Cameroon]Immediate antiretroviral therapy in young HIV-infected children: benefits and risks.Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.False negative HIV antibody test in HIV infected children who receive early antiretroviral treatment in a resource-limited setting.Prevalence of human leukocyte antigen-B*5701 among HIV-infected children in Thailand and Cambodia: implications for abacavir use.Optimizing antiretroviral therapy in adolescents with perinatally acquired HIV-1 infection.Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.
P2860
Q24194589-39148DDC-0857-4275-8FD8-7EDD7C77D374Q24202004-B8B0E651-C882-42B8-A00D-6EECA782F9D5Q28484394-46C4893F-A101-4049-9D7D-FCB25F631850Q30359339-47690CCD-7B9D-4B78-901C-8365336BF6FEQ33413634-F49BEEAB-FCC8-4B84-BC32-0216FDDA8139Q33748141-AEE943CD-0076-4570-900F-AC20D849F863Q33827819-34BE582A-5153-4BD0-8945-0CC14338B8BEQ33884183-1CEC445B-E674-46D0-B93B-F26718B4EBDAQ33926151-0E98E68A-0BF2-491A-A13E-A802CB6C2F6CQ34215346-DA18D834-2301-4CCD-A638-4013126674C8Q34251138-0EB65925-398D-4253-963C-6516378A0E51Q34367468-A9F34888-C32E-4720-8845-6795FA2A0FCAQ34410947-8B16E873-5958-4805-A20D-3A0096E2EE53Q34483451-E0402ECA-B53F-408E-8317-8C7B11243260Q34692768-8C94E607-6140-4D8F-9FF7-85E7CEB6CA5EQ34997180-B6DDE6B5-EE33-4A09-8388-F9EBD41C4821Q35034306-8FABB434-867D-4D1F-B3D5-D036F40A14E8Q35488671-D6FC494D-B827-4B1C-BAE9-C366DCAF51CFQ35547048-24A14720-FD76-4839-BF03-70C95D9DF47DQ35557224-8C9BFB7D-96E7-4F3E-88A3-0DA8E651F696Q35635685-1D04DA3A-AB47-4801-8F48-D19EA07EA5EAQ35677644-8BE29E99-9588-4433-8D81-5DEA5AE62F15Q35722000-88CD07D7-64B6-46D2-A2AE-211DFE9745DBQ35963854-2451F1A7-6366-402E-9D0B-193895D27E4BQ36015636-7FA3C73A-E6CA-46F5-A630-73F61FFD8A3FQ36036400-9C361799-26A6-4E8F-90EC-7596D4B150FEQ36087922-44CB1A3C-AB7C-419F-9571-AF142D34F3FEQ36206191-23710F0A-17E6-4E17-AC64-8CD161FF1906Q36301325-FBCB622F-F783-447D-8113-2BF2D2EDEC26Q36311894-D7F7DF58-1A02-4EFB-85C0-0DC5224D6F50Q36941659-1FC0D424-B460-4A96-8C10-F9D7E40D0CDFQ36948138-BA806C87-767C-4B10-826E-0C9FD3AC6742Q37029110-89AE0A17-E03F-44C2-AAEE-B2EF57BC8A70Q37260613-2AA23847-2B6C-49FA-B97B-F335F1CA6B0AQ37403284-4C095D8C-4096-4CA4-A431-F4453E0C1F35Q37439512-7B5C3196-98A5-4E69-90CB-AD2F8D4EDFF3Q37482026-3F5BC9CD-6D28-446D-987E-CAC5E99C179DQ37638863-71D6D191-F1AA-4C87-A217-5F5853BA856FQ37816391-9B9900B8-C56E-4250-803A-E97329686458Q37835819-9CD1B5D6-5D0E-44EB-B619-78F0FCD5D904
P2860
PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
PENTA 2009 guidelines for the ...... in paediatric HIV-1 infection.
@en
PENTA 2009 guidelines for the ...... in paediatric HIV-1 infection.
@nl
type
label
PENTA 2009 guidelines for the ...... in paediatric HIV-1 infection.
@en
PENTA 2009 guidelines for the ...... in paediatric HIV-1 infection.
@nl
prefLabel
PENTA 2009 guidelines for the ...... in paediatric HIV-1 infection.
@en
PENTA 2009 guidelines for the ...... in paediatric HIV-1 infection.
@nl
P2093
P50
P1433
P1476
PENTA 2009 guidelines for the ...... in paediatric HIV-1 infection.
@en
P2093
Albert Faye
Alexandra Compagnucci
Carlo Giaquinto
Christoph Königs
Deepak Patel
Diane Bastiaans
E G Hermione Lyall
Gareth Tudor-Williams
Guido Castelli Gattinara
José Tomas Ramos Amador
P304
P356
10.1111/J.1468-1293.2009.00759.X
P577
2009-11-01T00:00:00Z